Name:
Alugel A susp.d / vn.prim. in vial 170ml in pack No. 1
Description:
Suspension of white or almost white color with a lemon smell. Stratification of the suspension is allowed, which is eliminated by shaking. The main active ingredient Algeldrate + magnesium hydroxide + benzocaine Suspension for internal use Dosage 170 ml Indications for use Antacid therapy for heartburn and gastroesophageal reflux, accompanied by pain. Dosage and administration Before use, the vial with the drug should be shaken thoroughly to obtain a homogeneous suspension! Take 5-10 ml 3-4 times a day 10-15 minutes before meals. When taking the suspension, it is not recommended to drink it with liquid. If you miss a dose, you just need to take the next one at the usual time for taking it, you should not double the dose to make up for the missed one. Do not exceed recommended doses. The maximum duration of admission without consulting a doctor is 7 days. The need for further treatment is determined by the doctor. The drug is contraindicated in children and adolescents under 18 years of age. Use in patients with renal insufficiency In patients with mild to moderate renal insufficiency, it is recommended to take the drug under the direct supervision of a physician, because. in this category of patients, it may be necessary to reduce the daily dose or lengthen the intervals between doses, depending on the severity of the violations. The drug Alugel A is contraindicated in severe renal failure (see sections “Precautions”, “Contraindications”). Use during pregnancy and lactationAlugel A is not prescribed during pregnancy and lactation, as it contains benzocaine. Precautions It is necessary to observe a 2-hour interval between the use of Alugel A and other drugs (when taking antimicrobial agents of the fluoroquinolone series – 4 hours). The patient should be aware of the need to consult a doctor in case of: weight loss; difficulty swallowing and persistent abdominal discomfort; digestive disorders that appeared for the first time, changes in existing digestive disorders; kidney failure. Use is not recommended in patients with severe chronic constipation, suspected acute appendicitis, in the presence of metabolic alkalosis, cirrhosis of the liver, severe heart failure, toxemia of pregnancy, ulcerative colitis, diverticulosis, colostomy or ileostomy (increased risk of developing fluid and electrolyte imbalance), with chronic diarrhea, exacerbation of hemorrhoids, impaired renal function (creatinine clearance <30 ml / min, risk of hypermagnesemia and aluminum intoxication). Aluminum hydroxide can cause constipation, an overdose of magnesium salts can lead to intestinal hypokinesia, taking high doses of the drug can cause or aggravate intestinal obstruction in patients with an increased risk of such complications, i.e. in patients with renal insufficiency or in the elderly. Aluminum hydroxide is poorly absorbed from the gastrointestinal tract, so systemic effects are rarely observed in patients with normal renal function. However, high doses of the drug or long-term use of the drug, as well as the use of recommended doses in patients with a low phosphorus diet, can lead to phosphate deficiency (due to the ability of aluminum to bind phosphate ions), accompanied by increased bone resorption, hypercalciuria and the risk of developing osteomalacia. In this regard, it is recommended to visit a doctor in case of prolonged use of a medicinal product containing aluminum and magnesium compounds, as well as in the presence of risks of phosphorus deficiency in the body. If during the recommended maximum duration of treatment (7 days) the symptoms persist or the condition worsens, you should definitely consult a doctor so that he establishes the cause, rechecks the correctness of the diagnosis and revises the treatment. In the case of patients with renal insufficiency or those on chronic dialysis, the content of aluminum and magnesium in the medicinal product must be taken into account. With prolonged use at high doses, including high therapeutic doses, it is possible to develop encephalopathy, dementia, microcytic anemia, or worsening of osteomalacia caused by dialysis. Aluminum hydroxide may not be safe for porphyria patients on hemodialysis. Patients with mild to moderate renal insufficiency are advised to take the drug under the direct supervision of a physician. In these patients, prolonged use of the drug Alugel A should especially be avoided. When taking the drug, numbness and anesthesia of the oral mucosa and tongue occur. This phenomenon is transient and does not require therapeutic measures. During treatment with Alugel A, it is necessary to avoid the use of alcohol and acids (lemon juice, vinegar, etc.) due to the possibility of weakening the local anesthetic effect of benzocaine. Alugel A should not be taken by patients with intolerance to local anesthetics such as esters (especially derivatives of para-aminobenzoic acid), parabens or paraphenylenediamine due to possible intolerance to benzocaine). Alugel A contains sorbitol, which allows its use in patients with diabetes mellitus, but should not be taken in patients with congenital fructose intolerance, as this can cause stomach irritation and diarrhea. Calorie content of one dose of Alugel A (5 ml of suspension) - 1.5 kcal; 10 ml of suspension - 3.0 kcal; 15 ml - 4.5 kcal; the maximum daily dose (40 ml) - 12 kcal. Alugel A contains parabens (parahydroxybenzoates), as a result of which the use of this drug may cause allergic reactions (possibly delayed). The content of ethanol (ethyl alcohol) in the medicinal product is 2.5 vol. %, i.e. 98.1 mg in a single dose (5 ml), which is equivalent to 2.5 ml of beer, 1 ml of wine, or 196.2 mg of ethanol in 10 ml of the drug, which is equivalent to 5 ml of beer, 2 ml of wine, or 294.3 mg of ethanol at a dose of 15 ml, which is equivalent to 7.5 ml of beer, 3 ml of wine. It is dangerous to apply to patients suffering from alcoholism. Consideration should also be given to high-risk patients, including those with liver disease and epilepsy. Contraindications Hypersensitivity to active substances (as well as to other local anesthetics of the amide series) or to any of the auxiliary components of the drug. Rare congenital fructose intolerance. Severe renal insufficiency (since the drug contains magnesium). Age up to 18 years. During pregnancy and breastfeeding. Porfiry. Cachexia. Side effects Adverse reactions are classified according to frequency and system organ class. The frequency is defined as follows: very often (?1/10), often (?1/100 to <1/10), infrequently (?1/1000 to <1/100), rarely (?1/10000 to <1/10 1000), very rare (<1/10000), unknown (cannot be estimated from the available data). Immune system disorders Frequency unknown: hypersensitivity reactions such as pruritus, erythema, urticaria, angioedema, anaphylactic reactions. Possible local reactions at the site of application (due to the presence of benzocaine). Gastrointestinal disorders Uncommon: diarrhea or constipation. In rare cases, nausea, vomiting, changes in taste sensations may occur. Metabolic and nutritional disorders Frequency unknown: cases of hypermagnesemia and elevated levels of aluminum in the blood have been reported. Cases of hypermagnesemia were observed mainly in patients with renal insufficiency, hyperaluminemia - in patients with renal insufficiency and / or the elderly. The risk is increased with concomitant oral administration of citric acid, sodium citrate, or calcium citrate. Hypophosphatemia may develop after long-term use or high doses, as well as use at recommended doses in patients whose diet is characterized by a low content of phosphorus, which can lead to increased bone resorption processes and the occurrence of hypercalciuria with an increased risk of osteomalacia. If you experience any of these or any other adverse reactions not listed in this section, you should consult your doctor. Each 5 ml suspension contains active substances: aluminum hydroxide gel in terms of aluminum oxide - 218 mg; magnesium hydroxide paste in terms of magnesium oxide - 75 mg and benzocaine - 109 mg; excipients: non-crystallizing sorbitol solution, ethyl alcohol 96%, hydroxyethyl cellulose, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), butyl parahydroxybenzoate, lemon oil, sodium saccharin, purified water. Overdose Magnesium overdose does not usually cause toxic reactions in patients with normal renal function. However, magnesium poisoning can develop in patients with renal insufficiency (see section "Precautions"). Symptoms of an acute overdose of aluminum hydroxide and magnesium hydroxide combination include diarrhea, abdominal pain, and vomiting. High doses of the drug may cause or exacerbate intestinal obstruction in patients with an increased risk of such complications. The toxic effect depends on the concentration of magnesium in the blood serum. Signs of toxic action: lowering blood pressure; nausea, vomiting; drowsiness, decreased reflexes, muscle fatigue, neuromuscular paralysis; bradycardia, deviation of ECG results; hypoventilation; in the most severe cases, respiratory paralysis, coma, impaired renal or cardiac function may develop; anuric syndrome. Aluminum and magnesium are excreted through the urinary tract. Treatment of magnesium overdose: rehydration, forced diuresis. In case of renal insufficiency, hemodialysis or peritoneal dialysis is necessary. Adverse reactions Adverse reactions are classified according to frequency and system organ class. The frequency is defined as follows: very often (?1/10), often (?1/100 to <1/10), infrequently (?1/1000 to <1/100), rarely (?1/10000 to <1/10 1000), very rare (<1/10000), unknown (cannot be estimated from the available data). Immune system disorders Frequency unknown: hypersensitivity reactions such as pruritus, erythema, urticaria, angioedema, anaphylactic reactions. Possible local reactions at the site of application (due to the presence of benzocaine). Gastrointestinal disorders Uncommon: diarrhea or constipation. In rare cases, nausea, vomiting, changes in taste sensations may occur. Metabolic and nutritional disorders Frequency unknown: cases of hypermagnesemia and elevated levels of aluminum in the blood have been reported. Cases of hypermagnesemia were observed mainly in patients with renal insufficiency, hyperaluminemia - in patients with renal insufficiency and / or the elderly. The risk is increased with concomitant oral administration of citric acid, sodium citrate, or calcium citrate. Hypophosphatemia may develop after long-term use or high doses, as well as use at recommended doses in patients whose diet is characterized by a low content of phosphorus, which can lead to increased bone resorption processes and the occurrence of hypercalciuria with an increased risk of osteomalacia. If you experience any of these or any other adverse reactions not listed in this section, you should consult your doctor. Storage conditionsKeep in a place protected from light, at a temperature not exceeding 25°C. Do not freeze. Keep out of the reach of children. Buy Alugel A oral suspension 170ml No. 1 Price for Alugel A oral suspension 170 ml No. 1 Instructions for use for Alugel A oral suspension 170 ml No. 1
INN | ALUMINUM HYDROXIDE, MAGNESIUM HYDROXIDE, BENZOCAINE |
---|---|
The code | 97 196 |
Barcode | 4 810 368 011 305 |
Dosage | 170ml |
Active substance | Aluminum hydroxide, magnesium hydroxide, benzocaine |
Manufacturer | Pharmland SP LLC, Belarus |
Be the first to review “Alugel A oral suspension 170ml №1” Cancel reply
Related products
Gastrointestinal tract
Drotaverine g / x solution for injection 20mg / ml amp 2ml cont ball pack No. 5×1
$8.00
Gastrointestinal tract
$8.00
Reviews
There are no reviews yet.